ALTASCIENCES
9.5.2023 16:01:28 CEST | Business Wire | Press release
Altasciences announced today that it has been recognized for excellence in contract research with a 2023 CRO Leadership Award for Capabilities. This marks the eighth year that Altasciences, a fully integrated drug development solution company, has been deemed a top performer.
Clinical Leader and Life Science Leader teamed up with ISR Reports to assess 46 CROs on more than 20 performance metrics in ISR’s annual Quality Benchmarking survey.
“Survey participants are asked to evaluate CROs that they have had hands-on experience working with over the past 18 months,” explains Kevin Olson, CEO at Industry Standard Research. “Experiential data, as opposed to perceptual data, enable users of ISR’s market research to feel confident in their business decisions based on learnings from the recent experiences of their industry peers.”
The Capabilities category assesses respondents on a CRO’s ability to deliver a wide range of services, expertise, and resources across multiple therapeutic areas. For more than 25 years, Altasciences has been transforming the traditional outsourcing paradigm by building a one-stop outsourcing solution with end-to-end services that simplify and accelerate the early phase drug development process for its partners.
“We are thrilled to be recognized by our peers in the industry, and are proud to have exceeded the expectations of small and large pharmaceutical companies,” says Chris Perkin, CEO at Altasciences. “Our ability to innovate and deliver a broad range of high-quality, integrated solutions for our clients is what sets us apart, and this award is a testament to the breadth of expertise our team brings to client projects and science each and every day.”
With nine strategically placed research and manufacturing facilities across North America, Altasciences helps safely speed its partners’ lead candidate selection to clinical proof of concept and beyond.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005179/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sisvel Website Now Available in Chinese and Japanese12.2.2026 10:30:00 CET | Press release
Chinese and Japanese language versions of the Sisvel corporate website are now live, delivering an enhanced experience for users in two of the world’s key technology markets. The move also reflects the growing role of Asia-based innovators and implementers in Sisvel licensing programmes. The localised sites will enable more SEP licensing stakeholders to access patent pool information and programme details in their native languages. All versions of the website will be updated continuously to carry the full range of Sisvel news and insights. “Sisvel is deeply embedded in the markets where we operate,” says Sisvel Executive Head of Brand Giulia Dini. “Our expanded online presence in Asia, which also includes the recent launch of an official WeChat channel, aligns with our growing physical footprint in the region. We look forward to driving the global conversation on patent licensing and innovation.” In 2025, Sisvel appointed senior executives to run its operations in Japan and China. The
In the age of AI agents, Splio makes prediction the foundation of CRM and launches its AI-first CRM12.2.2026 09:30:00 CET | Press release
Splio is setting prediction as the new CRM standard and the future interface for AI agentsThe company has evolved Tinyclues AI, initially focused on predictive AI, into an AI enhanced with generative and agentic capabilities, now integrated at the core of its platform Commercial launch of the AI-first CRM powered by Tinyclues AI Launch of the Ask my CRM agent, an intelligent copilot to speed up decision-making and CRM execution based on customer data The company is positioning itself as an AI-first company, already generating 30% of its revenue from AI and aiming for 50% in 2027 Splio announces the launch of its AI-first CRM powered by Tinyclues AI. Now integrated at the core of the platform, predictive AI helps brands orchestrate and personalize their communications at scale across every channel (email, SMS, RCS, WhatsApp...). Splio also unveils "Ask My CRM," its new AI agent designed as an intelligent marketing copilot that, plugged into each brand's customer data, makes customer kno
Stafford Capital Partners Announces New Renewable Energy Investment Strategy with Dedicated Team12.2.2026 09:00:00 CET | Press release
Stafford Capital Partners integrates dedicated renewables team tostrengthen the firm’s strategic infrastructure investing capabilities with a focus on energy transition opportunities. Stafford Capital Partners (“Stafford”), a leading international private markets investment and advisory firm, today announced the launch of a new strategy focused on the renewable energy sector. This initiative leverages the ongoing transformation and rapid growth within the renewables market, targeting the revamping and repowering of existing renewable assets to deliver compelling risk-adjusted returns while accelerating the transition to a low-carbon economy. This new strategic initiative further strengthens Stafford’s position in the global infrastructure investment market, providing institutions with access to a pioneering investment approach to renewable investing. This mirrors the differentiated approach Stafford has taken in developing its secondary market strategies across its real assets platform
KARL LAGERFELD Reunites With Paris Hilton for Spring – Summer 2026 “From Paris with Love” Campaign12.2.2026 08:00:00 CET | Press release
KARL LAGERFELD unveils its Spring–Summer 2026 campaign, From Paris with Love, starring cultural icon Paris Hilton for the second consecutive season. Captured through the lens of long-time brand collaborator Chris Colls at the Maison’s headquarters, 21 Rue Saint-Guillaume in Paris, the global campaign spans the KARL LAGERFELD, KARL LAGERFELD JEANS, and KARL LAGERFELD PARIS collections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211077844/en/ KARL LAGERFELD SS26 Campaign Paris Hilton - ©Chris Colls “Shooting the campaign at 21 Rue Saint-Guillaume was incredibly inspiring,” says Paris Hilton. “Stepping into Karl’s world felt personal and true to the DNA of both Karl and the brand. It wasn’t about looking back but being present in a space where his legacy continues to evolve.” Moving through the Maison with ease and confidence, Paris Hilton brings her signature glamour and charisma to KARL LAGERFELD’s universe through pla
AB InBev Reports Full Year and Fourth Quarter 2025 Results12.2.2026 07:01:00 CET | Press release
Underlying EPS increased by 6% with continued margin expansion and free cash flow generation of 11.3 billion USD Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211688662/en/ Figure 14. Terms and debt repayment schedule as of 31 December 2025 (billion USD) Regulated and inside information1 “Beer plays an important role in bringing people together and creating moments of celebration. In 2025, we executed our strategy, made disciplined capital allocation choices and delivered growth within our outlook for the year, even as we navigated a dynamic consumer environment. We exit 2025 with improved momentum and enter 2026 well positioned to engage consumers with our megabrands and an unparalleled lineup of mega platforms. Thank you to our colleagues for their ongoing commitment, hard work and passion for our business.” – Michel Doukeris, CEO, AB InBev Revenue 4Q +
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom